Chiesi.jpg
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
April 12, 2023 07:00 ET | Amryt Pharma plc
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for...
amryt-logo.png
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
April 03, 2023 07:00 ET | Amryt Pharma plc
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt...
amryt-logo.png
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
March 22, 2023 11:00 ET | Amryt Pharma plc
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq:...
amryt-logo.png
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
February 16, 2023 07:00 ET | Amryt Pharma plc
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 Dublin, Ireland, February 16, 2023 Amryt Pharma...
Chiesi Logo
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
January 08, 2023 15:00 ET | Amryt Pharma plc
                                        Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at...
amryt-logo.png
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
January 05, 2023 07:00 ET | Amryt Pharma plc
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (Nasdaq: AMYT), a global, commercial-stage...
amryt-logo.png
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
December 19, 2022 07:00 ET | Amryt Pharma plc
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN, Ireland, and Boston MA, December 19, 2022 Amryt...
amryt-logo.png
European Commission approves Mycapssa® for the treatment of Acromegaly
December 05, 2022 07:00 ET | Amryt Pharma plc
European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial ...
amryt-logo.png
Amryt Announces New Patent for Mycapssa®
November 30, 2022 07:00 ET | Amryt Pharma plc
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
amryt-logo.png
Amryt Reports Q3 2022 Financial and Operational Results
November 03, 2022 07:00 ET | Amryt Pharma plc
Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M...